JP2011516613A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516613A5
JP2011516613A5 JP2011505164A JP2011505164A JP2011516613A5 JP 2011516613 A5 JP2011516613 A5 JP 2011516613A5 JP 2011505164 A JP2011505164 A JP 2011505164A JP 2011505164 A JP2011505164 A JP 2011505164A JP 2011516613 A5 JP2011516613 A5 JP 2011516613A5
Authority
JP
Japan
Prior art keywords
composition
posaconazole
infection
pharmaceutical composition
acetate succinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011505164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516613A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/040653 external-priority patent/WO2009129301A2/en
Publication of JP2011516613A publication Critical patent/JP2011516613A/ja
Publication of JP2011516613A5 publication Critical patent/JP2011516613A5/ja
Withdrawn legal-status Critical Current

Links

JP2011505164A 2008-04-15 2009-04-15 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物 Withdrawn JP2011516613A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4517708P 2008-04-15 2008-04-15
US61/045,177 2008-04-15
PCT/US2009/040653 WO2009129301A2 (en) 2008-04-15 2009-04-15 Oral pharmaceutical compositions in a molecular solid dispersion

Publications (2)

Publication Number Publication Date
JP2011516613A JP2011516613A (ja) 2011-05-26
JP2011516613A5 true JP2011516613A5 (enExample) 2013-03-21

Family

ID=41165581

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505164A Withdrawn JP2011516613A (ja) 2008-04-15 2009-04-15 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物

Country Status (6)

Country Link
US (1) US20110034478A1 (enExample)
EP (1) EP2278957A2 (enExample)
JP (1) JP2011516613A (enExample)
AU (1) AU2009236290A1 (enExample)
CA (1) CA2720851A1 (enExample)
WO (1) WO2009129301A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104983701A (zh) * 2008-04-15 2015-10-21 默沙东公司 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
EP2723452A2 (en) 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs
WO2013123254A1 (en) 2012-02-15 2013-08-22 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
US9493582B2 (en) 2012-02-28 2016-11-15 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
HK1213585A1 (zh) 2012-10-22 2016-07-08 Cydex Pharmaceuticals, Inc. 烷基化环糊精组合物及其制备和使用方法
WO2014196519A1 (ja) 2013-06-03 2014-12-11 信越化学工業株式会社 加熱溶融押出用組成物及びこれを用いた加熱溶融押出成型物の製造方法
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
EP3183295B1 (en) 2014-08-22 2023-08-02 CyDex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
AU2015348043B2 (en) 2014-11-21 2019-08-22 F2G Limited Antifungal agents
US11058682B2 (en) * 2015-08-08 2021-07-13 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
EP3925601B1 (en) 2016-02-26 2024-07-17 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
WO2017032908A1 (en) * 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
CN106265526A (zh) * 2016-09-22 2017-01-04 山东大学 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用
WO2020159562A1 (en) 2019-01-29 2020-08-06 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
WO2022034232A1 (en) 2020-08-13 2022-02-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant high-strength formulation containing posaconazole
EP4119128A1 (en) * 2021-07-13 2023-01-18 Dr. Falk Pharma Gmbh Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion
AU2022324717A1 (en) 2021-11-25 2024-06-13 Alfred E. Tiefenbacher (Gmbh Und Co. Kg) Granules containing posaconazole
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
CN117545470A (zh) * 2023-09-18 2024-02-09 北京德立福瑞医药科技有限公司 泊沙康唑固体分散体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
US5790957A (en) * 1995-09-12 1998-08-04 Nokia Mobile Phones Ltd. Speech recall in cellular telephone
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
TR200003598T2 (tr) * 1998-03-26 2001-06-21 Japan Tobacco Inc. Amid türevleri ve nosiseptin antagonistleri
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
BR0208626A (pt) * 2001-04-03 2004-03-09 Schering Corp Composição antifúngica com biodisponibilidade intensificada
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
WO2006034080A2 (en) * 2004-09-17 2006-03-30 Nektar Therapeutics Formulation comprising itraconazole
US20060275230A1 (en) * 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
JP2009514884A (ja) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル
CN104983701A (zh) * 2008-04-15 2015-10-21 默沙东公司 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物

Similar Documents

Publication Publication Date Title
JP2011516613A5 (enExample)
de Lacerda Coriolano et al. Antibacterial and antibiofilm potential of silver nanoparticles against antibiotic-sensitive and multidrug-resistant Pseudomonas aeruginosa strains
Huang et al. Self-assemblies based on traditional medicine berberine and cinnamic acid for adhesion-induced inhibition multidrug-resistant Staphylococcus aureus
Pi et al. Macrophage‐targeted isoniazid–selenium nanoparticles promote antimicrobial immunity and synergize bactericidal destruction of tuberculosis bacilli
Zhou et al. The battle for autophagy between host and influenza A virus
Macedo et al. Usnic acid: From an ancient lichen derivative to promising biological and nanotechnology applications
Sharma et al. Immunomodulatory activities of curcumin-stabilized silver nanoparticles: Efficacy as an antiretroviral therapeutic
Ng et al. In vitro evaluation of curcumin‐encapsulated chitosan nanoparticles against feline infectious peritonitis virus and pharmacokinetics study in cats
Do et al. Advances in silver nanoparticles: unraveling biological activities, mechanisms of action, and toxicity
Michaelis et al. Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A
CL2010001358A1 (es) Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina.
CL2009000902A1 (es) Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica.
Lou et al. Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice
Suresh et al. Therapeutic potential of curcumin in ARDS and COVID‐19
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
Yoosefian et al. Silver nanoparticle-based drug delivery systems in the fight against COVID-19: enhancing efficacy, reducing toxicity and improving drug bioavailability
Rai et al. Harnessing bioactive nanocurcumin and curcumin nanocomposites to combat microbial pathogens: a comprehensive review
Shin et al. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate
Zeng et al. Natural products and nanotechnology against coronavirus disease 2019
Sotoudeheian et al. Targeting SIRT1 by scopoletin to inhibit XBB. 1.5 COVID-19 life cycle
Patel et al. Potential of nanotechnology-based formulations in combating pulmonary infectious diseases: a current scenario
A Marathe et al. Herbal cocktail as anti-infective: promising therapeutic for the treatment of viral diseases
Vartak et al. Nanomedicine for the Treatment of Vaginal Candidiasis
WO2014197510A1 (en) Composition prepared from saikosaponin, the use and the preparation method thereof
RU2017125150A (ru) Фармацевтическая композиция для лечения или создания условий ремиссии у пожилого пациента с раком или у пациента на терминальной стадии рака